A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

Trial Identifier: D9260C00003
Sponsor: AstraZeneca
Collaborator:
Daiichi Sankyo
Start Date: October 2025
Primary Completion Date: February 2028
Study Completion Date: February 2028
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100021
CN Changsha, CN, 410013
CN Guangzhou, CN, 510060
CN Linyi, CN, 276001
CN Shandong, CN, 250117
CN Wuhan, CN, 430071
CN Zhengzhou, CN, 450008
ES A Coruña, ES, 15006
ES Barcelona, ES, 08035
ES Granada, ES, 18007
ES Madrid, ES, 28040
ES Madrid, ES, 28033
ES Sevilla, ES, 41009
ES Valencia, ES, 46009
FR Clermont-Ferrand, FR, 63050
FR La Roche sur Yon, FR, 85925
FR Montpellier, FR, 34070
FR Paris, FR, 75005
FR PIERRE BENITE, FR, 69310
IT Aviano, IT, 33081
IT Firenze, IT, 50134
IT Meldola, IT, 47014
IT Milano, IT, 20141
IT Napoli, IT, 80131
IT Roma, IT, 00168
KR Bukgu, KR, 41404
KR Goyang-si, KR, 410-769
KR Seoul, KR, 3722
KR Seoul, KR, 06273
KR Seoul, KR, 5505
KR Seoul, KR, 136705
KR Seoul, KR, 06351
KR Seoul, KR, 03080
KR Seoul, KR, 06591
US, IN Fort Wayne, IN, US, 46825
US, NE Omaha, NE, US, 68130
US, NY New York, NY, US, 10021
US, TX Houston, TX, US, 77024
US, WA Puyallup, WA, US, 98373